Growth Factor News and Research

RSS

Research uncovers mechanism that may help develop new strategies for osteoporosis treatment

Osteoporosis, a condition characterized by weak and fragile bones, develops when there is an imbalance in the remodeling process and more bone is lost than replaced. Now, new research published by Cell Press in the November issue of the journal Cell Stem Cell uncovers a mechanism that may guide development of better strategies for treatment osteoporosis.

8 Nov 2010

AVEO third quarter total collaboration revenues increase to $6.2 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced updated financial guidance and third quarter financial results, as well as recent developments.

4 Nov 2010

Novel serum test may help diagnose early pregnancy location and outcome

Researchers may have identified a promising novel diagnostic biomarker for ectopic pregnancy, according to a study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). In the western world, deaths from ectopic pregnancy are not common but in the developing world one in ten women who are admitted with an ectopic pregnancy die.

4 Nov 2010

Celldex third quarter net loss increases to $9.1 million

Celldex Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2010. Celldex reported a net loss of $9.1 million, or $0.28 per share, for the third quarter of 2010 compared to a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009. For the nine months ended September 30, 2010, Celldex reported a net loss of $25.2 million, or $0.79 per share, compared to a net loss of $23.6 million, or $1.49 per share, for the nine months ended September 30, 2009.

2 Nov 2010

Acorda reports net income of $12.4 million for third quarter 2010

Acorda Therapeutics, Inc. today announced its financial results for the third quarter of 2010.

1 Nov 2010

Laureate enters agreement with AVEO to produce AV-203 monoclonal antibody against ErbB3

Laureate Pharma, Inc., a full-service contract development and manufacturing organization, announced today that they have entered into a development and manufacturing agreement to produce AV-203, AVEO Pharmaceutical's (Cambridge, MA) novel monoclonal antibody targeted against ErbB3.

28 Oct 2010

Study finds association between KRAS p.G13D mutations and cetuximab treatment in colorectal cancer

Even though the cancer-treatment agent cetuximab is not considered effective treatment for KRAS (a gene)-mutated metastatic colorectal tumors, new research indicates that patients with colorectal cancer not responding to chemotherapy and a certain variation of this gene who were treated with cetuximab had longer overall and progression-free survival than patients with other KRAS-mutations, according to a study in the October 27 issue of JAMA.

27 Oct 2010

Research indicates stroma tissue provides new drug target for treating pancreatic cancer

A project focusing on the scar tissue surrounding cancer tumours aims to provide new targets for drugs for treating pancreatic cancer, the fifth highest cause of cancer deaths in the UK.

26 Oct 2010

FlexBone shows potential replacement for current bone transplantations

With a failure rate as high as 50 percent, bone tissue grafts pose a significant obstacle to orthopedic surgeons attempting to repair complex fractures or large areas of bone loss, such as those often caused by trauma and cancer. Current synthetic substitutes rarely possess the bone-like properties needed for successful grafting and are often difficult for surgeons to manipulate in the operating room. In response to these challenges, researchers at UMass Medical School have developed an easy-to-produce, inexpensive, synthetic bone material called FlexBone.

25 Oct 2010

Targeting c-Met protein may be effective for patients with metastatic liver cancer

A more personalized treatment for people with a type of metastatic liver cancer hepatocellular carcinoma may be possible by targeting the protein c-Met, according to Penn State College of Medicine researchers.

25 Oct 2010

Researchers identify common link among malignant tumor types in all grades of cancer

Researchers from Mount Sinai School of Medicine, in collaboration with investigators of the National Institute of Health and Medical Research (INSERM) of France led by Nicolae Ghinea, PhD, have found a common link among several malignant tumor types in all grades of cancer. This breakthrough may ultimately provide a new diagnostic or therapeutic target to detect cancer early or stop tumor growth.

21 Oct 2010

BioMarin announces BMN-111 program for treatment of achondroplasia

BioMarin Pharmaceutical Inc. today announced its program for BMN-111, a peptide therapeutic for the treatment of achondroplasia. BioMarin plans to file an IND in the fourth quarter of 2011 and to initiate a Phase 1 clinical trial by the first quarter of 2012.

19 Oct 2010

Acorda announces data of GGF2 preclinical studies for focal ischemic stroke

Acorda Therapeutics, Inc, today announced that data from preclinical studies show that Glial Growth Factor 2 (GGF2) promoted functional recovery following a permanent focal ischemic stroke.

19 Oct 2010

2010 AAO-MEACO meeting focuses on genetic medicine

Genetic medicine is the focus of two presentations at today's Scientific Program of the 2010 American Academy of Ophthalmology (AAO) Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting. The AAO-MEACO meeting is in session October 16 through 19 at McCormick Place, Chicago. It is the largest, most comprehensive ophthalmic education conference in the world.

18 Oct 2010

A new therapeutic approach for cancer

Trials are being organized for a new therapeutic approach to treating cancer, under exclusive license by Viral Genetics, Inc. According to Scott & White Healthcare Senior Vice President for Research Richard E. Beswick, M.D., who is also assistant dean of research at the Texas A&M Health Science Center College of Medicine, the trials will be conducted at the Glenda Tanner Vasicek Cancer Treatment Center, located at Scott & White in Temple, Texas.

15 Oct 2010

FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis

FibroGen, Inc. today announced initiation of a phase 2 study to compare the efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), with placebo in reversing liver fibrosis (scarring of the liver) due to chronic infection with hepatitis B virus (HBV).

15 Oct 2010

Combination of cetuximab and cisplatin chemotherapy benefits women with triple-negative breast cancer

European researchers have proven for the first time that targeting the epidermal growth factor receptor can provide substantial clinical benefit for women with hard-to-treat triple-negative breast cancer.

13 Oct 2010

Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer

For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.

11 Oct 2010

Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors

Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.

11 Oct 2010

Adding Cetuximab to chemo doubles response rate in hard-to-treat breast cancer

11 Oct 2010

Growth Factor News and Research

Research uncovers mechanism that may help develop new strategies for osteoporosis treatment

AVEO third quarter total collaboration revenues increase to $6.2 million

Novel serum test may help diagnose early pregnancy location and outcome

Celldex third quarter net loss increases to $9.1 million

Acorda reports net income of $12.4 million for third quarter 2010

Laureate enters agreement with AVEO to produce AV-203 monoclonal antibody against ErbB3

Study finds association between KRAS p.G13D mutations and cetuximab treatment in colorectal cancer

Research indicates stroma tissue provides new drug target for treating pancreatic cancer

FlexBone shows potential replacement for current bone transplantations

Targeting c-Met protein may be effective for patients with metastatic liver cancer

Researchers identify common link among malignant tumor types in all grades of cancer

BioMarin announces BMN-111 program for treatment of achondroplasia

Acorda announces data of GGF2 preclinical studies for focal ischemic stroke

2010 AAO-MEACO meeting focuses on genetic medicine

A new therapeutic approach for cancer

FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis

Combination of cetuximab and cisplatin chemotherapy benefits women with triple-negative breast cancer

Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer

Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors

Adding Cetuximab to chemo doubles response rate in hard-to-treat breast cancer

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News